10.24.13
Creganna-Tactx Medical, a Galway, Ireland-based provider of medical device outsourcing solutions, plans to use the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference (Oct. 27-Nov. 1) in San Francisco, Calif., to showcase its capabilities on the other side of the pond.
The firm is featuring the skills of its Center of Excellence for Emerging Therapies in Campbell, Calif. (about 50 miles south of San Francisco). One of the center’s many abilities is to help medical device companies develop breakthrough products for emerging minimally invasive therapies.
A single-site solution, the Campbell Center of Excellence provides services to deliver an approved medical device to market on behalf of its customers, according to the company’s management.
“Emerging therapies hold enormous commercial potential for our customers,” said David O’Keeffe, global vice president of Sales & Marketing at Creganna-Tactx Medical. “For example, the global transcatheter aortic valve replacement (TAVR) market is estimated to reach more than $1.5 billion by 2015. Over 40 companies are developing novel therapies for the potential $2 billion renal denervation market, while next generation technologies such as bioabsorbable stents are forecast to triple yearly growth for the next five years.”
O’Keeffe called the potential rewards “significant,” but noted that developing new categories of devices for emerging therapies is a “highly challenging” process.
“Our customers are breaking new ground. Choosing a knowledgeable commercialization partner with specialist insight accelerates that journey to market,” he said “Our Campbell team has played a remarkable role in partnering with pioneering companies to get these highly complex products into the hands of physicians faster and more efficiently.”
To celebrate the achievements of the Campbell Center of Excellence, an informal gathering of customers and those involved in device innovation throughout the Bay Area will be held during TCT. The company’s CEO, Chip Hance, who took the reins earlier this year, will host the evening along with the company’s previous CEO, its chairman, management and Campbell site team for a meet-and-greet event.
Companies interested in registering for the event on Oct. 30 should contact the company at: www.cregannaevents.com
During TCT, the company’s booth number is 1132.
In addition to its facility in Campbell, Creganna-Tactx also has U.S. offices in Minnesota and Ohio (Cleveland Clinic).
The firm is featuring the skills of its Center of Excellence for Emerging Therapies in Campbell, Calif. (about 50 miles south of San Francisco). One of the center’s many abilities is to help medical device companies develop breakthrough products for emerging minimally invasive therapies.
A single-site solution, the Campbell Center of Excellence provides services to deliver an approved medical device to market on behalf of its customers, according to the company’s management.
“Emerging therapies hold enormous commercial potential for our customers,” said David O’Keeffe, global vice president of Sales & Marketing at Creganna-Tactx Medical. “For example, the global transcatheter aortic valve replacement (TAVR) market is estimated to reach more than $1.5 billion by 2015. Over 40 companies are developing novel therapies for the potential $2 billion renal denervation market, while next generation technologies such as bioabsorbable stents are forecast to triple yearly growth for the next five years.”
O’Keeffe called the potential rewards “significant,” but noted that developing new categories of devices for emerging therapies is a “highly challenging” process.
“Our customers are breaking new ground. Choosing a knowledgeable commercialization partner with specialist insight accelerates that journey to market,” he said “Our Campbell team has played a remarkable role in partnering with pioneering companies to get these highly complex products into the hands of physicians faster and more efficiently.”
To celebrate the achievements of the Campbell Center of Excellence, an informal gathering of customers and those involved in device innovation throughout the Bay Area will be held during TCT. The company’s CEO, Chip Hance, who took the reins earlier this year, will host the evening along with the company’s previous CEO, its chairman, management and Campbell site team for a meet-and-greet event.
Companies interested in registering for the event on Oct. 30 should contact the company at: www.cregannaevents.com
During TCT, the company’s booth number is 1132.
In addition to its facility in Campbell, Creganna-Tactx also has U.S. offices in Minnesota and Ohio (Cleveland Clinic).